tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Amarin Corporation Reports Q2 2025 Financial Results

Amarin Corporation Reports Q2 2025 Financial Results

Amarin Corporation Plc ( (AMRN) ) has released its Q2 earnings. Here is a breakdown of the information Amarin Corporation Plc presented to its investors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amarin Corporation Plc is a pharmaceutical company focused on cardiovascular disease management, known for its product VASCEPA, which is used to reduce cardiovascular risk in patients. In its second quarter of 2025, Amarin reported an 8% increase in total net revenue, driven by its strategic partnership with Recordati for the commercialization of VAZKEPA in Europe. Despite a decrease in U.S. sales, the company saw significant growth in European and Rest-of-World markets. The company also initiated a global restructuring plan aimed at saving $70 million in operating expenses over the next year. Key financial highlights include a net loss of $14.1 million and a strong cash position of nearly $300 million. Looking forward, Amarin’s management is optimistic about achieving positive free cash flow and expanding the market reach of VASCEPA/VAZKEPA globally.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1